{"id":"NCT01029652","sponsor":"Novartis Pharmaceuticals","briefTitle":"Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study","officialTitle":"A 12 Weeks Randomized, Controlled Core Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective, Including a 12-week Double-blind Extension Study and an Open-label 48 Week Extension Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2009-12-10","resultsPosted":"2011-11-18","lastUpdate":"2014-01-30"},"enrollment":230,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Gout"],"interventions":[{"type":"DRUG","name":"Canakinumab 150 mg","otherNames":[]},{"type":"DRUG","name":"Triamcinolone acetonide 40 mg","otherNames":[]},{"type":"DRUG","name":"Placebo to canakinumab","otherNames":[]},{"type":"DRUG","name":"Placebo to triamcinolone acetonide","otherNames":[]}],"arms":[{"label":"Canakinumab 150 mg","type":"EXPERIMENTAL"},{"label":"Triamcinolone acetonide 40 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the 12-week core study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom non-steroidal anti-inflammatory drugs (NSAIDs) and/ or colchicine are contraindicated, not tolerated, or ineffective. The efficacy of canakinumab was compared to the corticosteroid triamcinolone acetonide.\n\nThe purpose of the first 12-week extension study was to collect additional safety, tolerability and efficacy data in patients who have completed the core study CACZ885H2356.\n\nThe purpose of the second 48 week open-label extension study was to collect additional long-term safety and tolerability data in patients who have completed the first extension study CACZ885H2356E1.","primaryOutcome":{"measure":"Time to First New Flare","timeFrame":"12 weeks","effectByArm":[{"arm":"Canakinumab 150 mg","deltaMin":null,"sd":null},{"arm":"Triamcinolone Acetonide 40 mg","deltaMin":null,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":47,"countries":["Australia","Belgium","Canada","Colombia","Estonia","Germany","Guatemala","Latvia","Lithuania","Mexico","Norway","Poland","Russia","Singapore","Sweden","Switzerland","Ukraine"]},"refs":{"pmids":["24122883"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":113},"commonTop":["Hypertension","Arthralgia","Nasopharyngitis","Headache","Bronchitis"]}}